EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Adverse Effects of Biologic Therapy: A Retrospective Cohort Study

Entela Shkodrani, Dorina Ruci, Alert Xhaja, Krisli Serani, Barbara Shkodrani, Viktoria Ruci

Pharmacoepidemiology · 26.05.2026 · 5 (2) · 15

DOI: 10.3390/pharma5020015 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology, online erschienen am 26.05.2026. Verfasst von Entela Shkodrani und 5 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate adverse effects associated with biologic therapy (Etanercept, Adalimumab, and Secukinumab) in patients with psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Methods

This retrospective observational study included 58 patients receiving biologic therapy: 40 with generalized plaque psoriasis, 13 with psoriatic arthritis, and 3 with hidradenitis suppurativa. Eligibility was based on national treatment protocols (Psoriasis Area and Severity Index [PASI] > 10; Hurley stage II–III). Demographic data, treatment duration, therapy modifications, discontinuations, and adverse events were collected from medical records. Patients were monitored for both efficacy and safety outcomes.

Results

Treatment discontinuation due to severe hepatotoxicity occurred in four patients (three receiving Etanercept and one Adalimumab), corresponding to 6.9% of the cohort. Adalimumab was discontinued in one patient due to cutaneous leishmaniasis after 24 months and in another due to pregnancy after 26 months. Upper limb edema was observed following a switch from Adalimumab to Secukinumab. One patient discontinued Etanercept due to lack of efficacy and subsequently died from a fatal methotrexate overdose. Treatment switches included Etanercept to Adalimumab for granulomatous uveitis (one case) and Adalimumab to Etanercept due to generalized urticaria (two cases).

Conclusion

Adverse events were relatively infrequent, with an overall incidence below 10% (6.9% for the most common event and

Zitieren

APA

Shkodrani, E., Ruci, D., Xhaja, A., Serani, K., Shkodrani, B., & Ruci, V. (2026). Adverse Effects of Biologic Therapy: A Retrospective Cohort Study. Pharmacoepidemiology, 5(2), 15. https://doi.org/10.3390/pharma5020015

Vancouver

Shkodrani E, Ruci D, Xhaja A, Serani K, Shkodrani B, Ruci V. Adverse Effects of Biologic Therapy: A Retrospective Cohort Study. Pharmacoepidemiology. 2026;5(2):15. doi:10.3390/pharma5020015

BibTeX
@article{Shkodrani2026,
  author = {Shkodrani, Entela and Ruci, Dorina and Xhaja, Alert and Serani, Krisli and Shkodrani, Barbara and Ruci, Viktoria},
  title = {Adverse Effects of Biologic Therapy: A Retrospective Cohort Study},
  journal = {Pharmacoepidemiology},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {15},
  doi = {10.3390/pharma5020015}
}
Kostenlos starten →